Lyndon Kim, MD

Contact Dr. Kim

900 Walnut Street
Suite 200
Philadelphia, PA 19107

(215) 955-7000

Medical School
Yonsei University College of Medicine, Korea - 1985

Residency
Brooklyn Hospital Caledonia
UMDNJ - Robert Wood Johnson University Hospital

Fellowship
Brown University School of Medicine
Massachusetts General Hospital, Boston, MA

Board Certification
Medical Oncology

Hospital Appointment
Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Hospital Appointment
Active Medical Staff

University Appointment
Associate Professor of Medical Oncology

Research and Clinical Interests
Medical Oncology, Brain Tumor

Publications

Most recent Peer-reviewed Publications

1. Pulmonary metastases in patients with recurrent, treatment-resistant meningioma: Prognosis and identification by 111indium-octreotide imaging
2. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas
3. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas
4. A phase I trial of enzastaurin in patients with recurrent gliomas
5. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
6. Erratum: Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme (Journal of Neuro-Oncology (2008) vol. 89 (339-357) 10.1007/s11060-008-9615-4)
7. Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme
8. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors
9. Chemotherapeutic options for primary brain tumors
10. Neoplastic meningitis.
11. Lipid-associated sialoprotein in the cerebrospinal fluid: Association with brain malignancies
12. White-matter abnormalities in unirradiated patients cured of primary central nervous system lymphoma
13. Concurrent chemotherapy and radiotherapy in patients with brain tumors
14. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors
15. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants
16. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas